Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
MEOBF's Cash to Debt is ranked higher than
90% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. MEOBF: No Debt )
MEOBF' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.64
MEOBF's Equity to Asset is ranked higher than
71% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. MEOBF: 0.64 )
MEOBF' s 10-Year Equity to Asset Range
Min: 0.64   Max: 0.97
Current: 0.64

0.64
0.97
F-Score: 1
Z-Score: 2.05
M-Score: -3.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -601.69
MEOBF's Operating margin (%) is ranked higher than
60% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. MEOBF: -601.69 )
MEOBF' s 10-Year Operating margin (%) Range
Min: -39225   Max: 2.77
Current: -601.69

-39225
2.77
Net-margin (%) -531.06
MEOBF's Net-margin (%) is ranked higher than
60% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. MEOBF: -531.06 )
MEOBF' s 10-Year Net-margin (%) Range
Min: -29639.29   Max: 307.32
Current: -531.06

-29639.29
307.32
ROE (%) -16.87
MEOBF's ROE (%) is ranked higher than
77% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. MEOBF: -16.87 )
MEOBF' s 10-Year ROE (%) Range
Min: -53.7   Max: 32.72
Current: -16.87

-53.7
32.72
ROA (%) -10.57
MEOBF's ROA (%) is ranked higher than
78% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. MEOBF: -10.57 )
MEOBF' s 10-Year ROA (%) Range
Min: -46.4   Max: 22.57
Current: -10.57

-46.4
22.57
ROC (Joel Greenblatt) (%) -61.40
MEOBF's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. MEOBF: -61.40 )
MEOBF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -33281.82   Max: 196.16
Current: -61.4

-33281.82
196.16
Revenue Growth (3Y)(%) -27.30
MEOBF's Revenue Growth (3Y)(%) is ranked higher than
64% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. MEOBF: -27.30 )
MEOBF' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -27.3
Current: -27.3

» MEOBF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MEOBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 22.99
MEOBF's Forward P/E is ranked higher than
90% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MEOBF: 22.99 )
N/A
P/B 2.00
MEOBF's P/B is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. MEOBF: 2.00 )
MEOBF' s 10-Year P/B Range
Min: 1.8   Max: 48.95
Current: 2

1.8
48.95
P/S 62.99
MEOBF's P/S is ranked higher than
50% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. MEOBF: 62.99 )
MEOBF' s 10-Year P/S Range
Min: 48.92   Max: 930
Current: 62.99

48.92
930
Current Ratio 4.77
MEOBF's Current Ratio is ranked higher than
75% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. MEOBF: 4.77 )
MEOBF' s 10-Year Current Ratio Range
Min: 1.82   Max: 21
Current: 4.77

1.82
21
Quick Ratio 4.77
MEOBF's Quick Ratio is ranked higher than
75% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. MEOBF: 4.77 )
MEOBF' s 10-Year Quick Ratio Range
Min: 1.82   Max: 21
Current: 4.77

1.82
21
Days Sales Outstanding 176.54
MEOBF's Days Sales Outstanding is ranked higher than
71% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. MEOBF: 176.54 )
MEOBF' s 10-Year Days Sales Outstanding Range
Min: 26.01   Max: 1147.14
Current: 176.54

26.01
1147.14

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 6.60
MEOBF's Price/DCF (Projected) is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MEOBF: 6.60 )
MEOBF' s 10-Year Price/DCF (Projected) Range
Min: 3.66   Max: 7.33
Current: 6.6

3.66
7.33
Price/Median PS Value 0.90
MEOBF's Price/Median PS Value is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. MEOBF: 0.90 )
MEOBF' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.27
Current: 0.9

0.7
2.27
Earnings Yield (Greenblatt) -9.80
MEOBF's Earnings Yield (Greenblatt) is ranked higher than
63% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. MEOBF: -9.80 )
MEOBF' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.8   Max: 0.1
Current: -9.8

-9.8
0.1

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 41 99 227 754
EPS($) -0.22 -0.15 0.25 1.14
EPS without NRI($) -0.22 -0.15 0.25 1.14

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MSB.Australia, LWB.Germany,
Mesoblast Ltd is an Australian biotechnology company. The Company is engaged in the development, manufacturing and commercialization of biological products for the field of regenerative medicine. Its products are for cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions. The Company and Teva Pharmaceutical Industries Ltd., have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK